REFERENCES
- Singh S, Wulf D, Hussain R, et al. Abortion worldwide: A decade of uneven progress. New York: Guttmacher Institute 2009.
- Sedgh G, Singh S, Henshaw SK, Bankole A. Legal abortion worldwide in 2008: Levels and recent trends. Int Perspect Sex Reprod Health 2011;37:84–94.
- Azerbaijan State Statistical Committee (SSC). Azerbaijan demographic and health survey 2006. Calverton, Maryland: Macro International Inc. 2008.
- Goldberg H, Serbanescu FI. Induced abortion in the Caucasus republics: A detailed analysis. International Union for the Scientific Study of Population XXV International Population Conference; 18–23 July 2005, Tours, France.
- Eastern-European Alliance for Reproductive Choice. Azerbaijan. Accessed 21 July 2012 from: http://www.reprochoice.org/azerbaijan.aspx
- World Health Organization. Safe abortion: Technical and policy guidance for health systems. Geneva: WHO, Department of Reproductive Health and Research 2012.
- Akin A, Dabash R, Dilbaz B, et al. Increasing women's choices in medical abortion: A study of misoprostol 400 μg swallowed immediately or held sublingually following 200 mg mifepristone. Eur J Contracept Reprod Health Care 2009;14:169–75.
- Arvidsson C, Hellborg M, Gemzell-Danielsson K. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. Eur J Obstet Gynecol Reprod Biol 2005; 123:87–91.
- Ho PC. Women's perceptions on medical abortion. Contraception 2006;74:11–5.
- Shannon C, Wiebe E, Jacot F, et al. Regimens of misoprostol with mifepristone for early medical abortion: A randomised trial. Br J Obstet Gynaecol 2006; 113:621–8.
- Swica Y, Chong E, Middleton T, et al. Acceptability of home use of mifepristone for medical abortion. Contraception 2013;88:122–7.
- Creinin MD, Gemzell-Danielsson K. Medical abortion in early pregnancy. In Paul M, Lichtenberg S, Borgatta L, et al., eds. Management of unintended and abnormal pregnancy: Comprehensive abortion care, 1st edn. Chichester, UK: Wiley-Blackwell 2009: 111–34.
- Winikoff B, Dzuba IG, Creinin MD, et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: A randomized controlled trial. Obstet Gynecol 2008;112:1303–10.
- Chong E, Tsereteli T, Nguyen NN, Winikoff B. A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion. Contraception 2012;86:251–6.
- Raghavan S, Comendant R, Digol I, et al. Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days’ LMP: A randomized controlled trial. Contraception 2010;82:513–519.
- Raghavan S, Maistruk G, Shochet T, et al. Efficacy and acceptability of early mifepristone-misoprostol medical abortion in Ukraine: Results of two clinical trials. Eur J Contracept Reprod Health Care 2013;18: 112–9.
- Raghavan S, Tsereteli T, Kamilov A, et al. Acceptability and feasibility of the use of 400 μg of sublingual misoprostol after mifepristone for medical abortion up to 63 days since the last menstrual period: Evidence from Uzbekistan. Eur J Contracept Reprod Health Care 2013; 18:104–11.